Cooperative Agreement W81XWH1920019

The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $858,841 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model monkeypox virus infection during pregnancy in vivo and ex vivo. The recipient will establish and characterize pregnancy models to study vertical transmission of monkeypox virus and understand how gestational age and viral clade influence infection outcomes. Work encompasses two...

The National Institute of Allergy and Infectious Diseases awarded The Research Foundation For The State University Of New York $227,115 on February 3, 2026, to investigate the role of adenine-rich (A-rich) regions in the Zika virus 3' untranslated region (3' UTR) and their interaction with cellular poly(A) binding protein (PABP1). The research addresses molecular mechanisms of Zika virus replication in the absence of effective licensed antivirals or vaccines. The project uses mutagenesis,...

The National Institute of Allergy and Infectious Diseases awarded the University of Louisville $1.395 million on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral compounds targeting the Zika virus NS4B protein. The project optimizes a benzamide-scaffold small-molecule series identified through ultra-high-throughput screening to inhibit formation of the Zika viral replicase complex. Deliverables include a preclinical therapeutic...

The National Institute of Allergy and Infectious Diseases awarded Yale University $182,728 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize Wolbachia-based interventions for arboviral prevention. The project develops statistical and mathematical models to identify factors influencing the speed of Wolbachia introgression into wild Aedes aegypti populations and to determine optimal release timing and dosing strategies. Wolbachia is an...

The National Institute of Allergy and Infectious Diseases awarded Kennesaw State University $517,956 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the effects of per- and polyfluoroalkyl substances (PFAS) on mosquito fitness and arbovirus transmission potential. The recipient will establish laboratory models of sublethal PFAS exposure across four mosquito species: Aedes albopictus (Zika virus vector), Aedes aegypti (Zika virus...

The National Institute of Child Health and Human Development awarded the University of Pennsylvania $465,870 on June 1, 2026, under the Child Health and Human Development Extramural Research Program (CFDA 93.865, Project Grant R01HD120540) to investigate postpartum maternal immune dynamics and viral disease outcomes. The research focuses on defining immune mechanisms underlying enhanced maternal resilience to severe viral infection during the postpartum period. The project includes two primary...

The National Institute of Allergy and Infectious Diseases awarded the University of South Florida $791,245 on May 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate placental antiviral defense mechanisms. The funded research, organized around two specific aims, will elucidate how human trophoblasts produce type III interferons and defend against viral threats at the maternal-fetal interface. Aim 1 will define the mechanisms by which...

The National Institute of Allergy and Infectious Diseases awarded Duke University $100,228 on January 17, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the RNA-binding landscape of flavivirus capsid protein. The recipient will characterize how dengue virus and Zika virus capsid protein binds to host cell RNA molecules, beyond its known role in packaging viral genomic RNA. Work in Aim 1 employs cell fractionation coupled with enhanced RNA-interactome...

The National Institute of Child Health and Human Development awarded Oregon Health & Science University $2.72 million on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate how maternal HIV infection and long-acting antiretroviral therapy affect fetal immune development using a rhesus macaque model of simian immunodeficiency virus infection. The research uses a translational animal model to distinguish the effects of HIV...

The National Institute of Allergy and Infectious Diseases awarded Case Western Reserve University $631,401 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop human monoclonal antibodies targeting Plasmodium vivax malaria. The research focuses on isolating and optimizing monoclonal antibodies (MAbs) that target the parasite's apical membrane protein 1 (AMA1) and circumsporozoite protein (CSP) to prevent and treat vivax malaria, which...